protocol
发表于 2025-3-21 20:06:54
书目名称Chronic Leukemias and Lymphomas影响因子(影响力)<br> http://impactfactor.cn/2024/if/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas影响因子(影响力)学科排名<br> http://impactfactor.cn/2024/ifr/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas网络公开度<br> http://impactfactor.cn/2024/at/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas网络公开度学科排名<br> http://impactfactor.cn/2024/atr/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas被引频次<br> http://impactfactor.cn/2024/tc/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas被引频次学科排名<br> http://impactfactor.cn/2024/tcr/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas年度引用<br> http://impactfactor.cn/2024/ii/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas年度引用学科排名<br> http://impactfactor.cn/2024/iir/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas读者反馈<br> http://impactfactor.cn/2024/5y/?ISSN=BK0226387<br><br> <br><br>书目名称Chronic Leukemias and Lymphomas读者反馈学科排名<br> http://impactfactor.cn/2024/5yr/?ISSN=BK0226387<br><br> <br><br>
nominal
发表于 2025-3-21 21:57:12
Book 2003es of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin‘s disease. In their integrated surveys of these chronic myeloproliferative a
突袭
发表于 2025-3-22 03:53:08
http://reply.papertrans.cn/23/2264/226387/226387_3.png
神经
发表于 2025-3-22 05:03:49
http://reply.papertrans.cn/23/2264/226387/226387_4.png
加花粗鄙人
发表于 2025-3-22 12:10:19
http://reply.papertrans.cn/23/2264/226387/226387_5.png
Diuretic
发表于 2025-3-22 16:19:37
2364-1134 d cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insightsinto the promising new era of antineoplastic pharmacology.978-1-4684-9732-8978-1-59259-308-8Series ISSN 2364-1134 Series E-ISSN 2364-1142
Diuretic
发表于 2025-3-22 18:17:01
http://reply.papertrans.cn/23/2264/226387/226387_7.png
异端
发表于 2025-3-22 21:40:48
http://reply.papertrans.cn/23/2264/226387/226387_8.png
LEERY
发表于 2025-3-23 03:46:15
Myeloproliferative Syndromes,logenous leukemia (CML). Several other clinical entities may be considered myeloproliferative as well (Table 1). It may not be possible to definitively classify a chronic myeloid disorder as either MDS or CMPDs because of overlapping clinical and pathologic features.
cleaver
发表于 2025-3-23 05:35:08
Advances in the Biology and Treatment of Multiple Myeloma,as well. Newer bisphosphonates may offer greater ease of administration, improved efficacy, and possibly even enhanced anti-tumor effect. Finally, thalidomide and other new agents offer new therapeutic alternatives to myeloma patients who were previously refractory to multiple agents.